IL1B and familial Mediterranean fever: In a systematic review by Moutschen et al. assessing the efficacy of IL‐1 antagonist therapy in FMF patients, it was reported that anakinra treatment was evaluated in 22 publications including 64 patients, while canakinumab was assessed in 8 studies involving 40 patients.